Going beyond the individual: how state-level characteristics relate to HPV vaccine rates in the United States.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
28 Feb 2019
Historique:
received: 14 08 2018
accepted: 20 02 2019
entrez: 2 3 2019
pubmed: 2 3 2019
medline: 24 4 2019
Statut: epublish

Résumé

The human papillomavirus (HPV) vaccine is an underutilized cancer control practice in the United States. Although individual contextual factors are known to impact HPV vaccine coverage rates, the impact of macro-level elements are still unclear. The aim of this analysis was to use HPV vaccination rates to explore the underuse of an evidence-based cancer control intervention and explore broader-level correlates influencing completion rates. A comprehensive database was developed using individual-level date from the National Immunization Survey (NIS)-Teen (2016) and state-level data collected from publically available sources to analyze HPV vaccine completion. Multi-level logistic models were fit to identify significant correlates. Level-1 (individual) and level-2 (state) correlates were fitted to a random intercept model. Deviance and AIC assessed model fit and sampling weights were applied. The analysis included 20,495 adolescents from 50 U.S. states and the District of Columbia. Teen age, gender, race/ethnicity, and maternal education were significant individual predictors of HPV completion rates. Significant state-level predictors included sex education policy, religiosity, and HPV vaccine mandate. States with the lowest HPV coverage rates were found to be conservative and highly religious. Little variation in vaccine exemptions and enacted sex and abstinence education polices were observed between states with high and low HPV vaccine coverage suggesting various contextual and situational factors impact HPV vaccine completion rates. Given that gender, religiosity, political ideology, and education policies are predictors of HPV vaccine completion, the interaction and underlying mechanism of these factors can be used to address the underutilization of the HPV vaccine.

Sections du résumé

BACKGROUND BACKGROUND
The human papillomavirus (HPV) vaccine is an underutilized cancer control practice in the United States. Although individual contextual factors are known to impact HPV vaccine coverage rates, the impact of macro-level elements are still unclear. The aim of this analysis was to use HPV vaccination rates to explore the underuse of an evidence-based cancer control intervention and explore broader-level correlates influencing completion rates.
METHODS METHODS
A comprehensive database was developed using individual-level date from the National Immunization Survey (NIS)-Teen (2016) and state-level data collected from publically available sources to analyze HPV vaccine completion. Multi-level logistic models were fit to identify significant correlates. Level-1 (individual) and level-2 (state) correlates were fitted to a random intercept model. Deviance and AIC assessed model fit and sampling weights were applied.
RESULTS RESULTS
The analysis included 20,495 adolescents from 50 U.S. states and the District of Columbia. Teen age, gender, race/ethnicity, and maternal education were significant individual predictors of HPV completion rates. Significant state-level predictors included sex education policy, religiosity, and HPV vaccine mandate. States with the lowest HPV coverage rates were found to be conservative and highly religious. Little variation in vaccine exemptions and enacted sex and abstinence education polices were observed between states with high and low HPV vaccine coverage suggesting various contextual and situational factors impact HPV vaccine completion rates.
CONCLUSIONS CONCLUSIONS
Given that gender, religiosity, political ideology, and education policies are predictors of HPV vaccine completion, the interaction and underlying mechanism of these factors can be used to address the underutilization of the HPV vaccine.

Identifiants

pubmed: 30819149
doi: 10.1186/s12889-019-6566-y
pii: 10.1186/s12889-019-6566-y
pmc: PMC6393974
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

246

Subventions

Organisme : NCI NIH HHS
ID : R01 CA214530
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA214530
Pays : United States

Références

MMWR Morb Mortal Wkly Rep. 1999 Apr 2;48(12):241-3
pubmed: 10220250
Int J Epidemiol. 2001 Jun;30(3):427-32; discussion 433-4
pubmed: 11416056
J Adolesc Health. 2006 Jan;38(1):72-81
pubmed: 16387256
N Engl J Med. 2007 May 10;356(19):1905-8
pubmed: 17494922
Sociol Health Illn. 2008 Sep;30(6):886-99
pubmed: 18761509
Soc Sci Med. 2009 Aug;69(3):475-80
pubmed: 19540642
BMC Med Res Methodol. 2009 Jul 14;9:49
pubmed: 19602263
Public Health Genomics. 2009;12(5-6):362-7
pubmed: 19684448
J Public Health Manag Pract. 2009 Sep-Oct;15(5):384-92
pubmed: 19704306
J Adolesc Health. 2010 Sep;47(3):242-8, 248.e1-248.e6
pubmed: 20708562
Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2187-98
pubmed: 20826829
Clin Pediatr (Phila). 2011 Feb;50(2):106-13
pubmed: 20837607
J Relig Health. 2013 Dec;52(4):1120-30
pubmed: 22076049
J Natl Med Assoc. 2011 Sep-Oct;103(9-10):960-7
pubmed: 22364066
Vaccine. 2012 May 21;30(24):3546-56
pubmed: 22480928
Clin Pediatr (Phila). 2013 Feb;52(2):162-70
pubmed: 23221308
Am J Public Health. 2013 Aug;103(8):1419-27
pubmed: 23763402
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2126-35
pubmed: 25028456
MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30
pubmed: 25167164
Lancet Infect Dis. 2015 Jan;15(1):8-9
pubmed: 25435053
Worldviews Evid Based Nurs. 2016 Oct;13(5):390-395
pubmed: 27458811
J Community Health. 2017 Jun;42(3):522-532
pubmed: 27778139
MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405-1408
pubmed: 27977643
Risk Manag Healthc Policy. 2017 Mar 13;10:29-32
pubmed: 28331378
Papillomavirus Res. 2017 Jun;3:142-148
pubmed: 28720448
Vaccine. 2017 Aug 16;35(35 Pt B):4540-4547
pubmed: 28736202
PLoS One. 2017 Aug 25;12(8):e0183725
pubmed: 28841681
Papillomavirus Res. 2016 Dec;2:46-51
pubmed: 29074185
MMWR Morb Mortal Wkly Rep. 2017 Nov 03;66(43):1171-1177
pubmed: 29095807
J Prim Care Community Health. 2017 Oct;8(4):349-362
pubmed: 29161946
Am J Public Health. 2018 Apr;108(4):493-499
pubmed: 29470122
Implement Sci. 2018 Mar 23;13(1):49
pubmed: 29566717
MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):909-917
pubmed: 30138305

Auteurs

Melissa Franco (M)

Prevention Research Center in St. Louis, Brown School, Washington University in St. Louis, One Brookings Drive, Campus Box 1196, St. Louis, MO, 63130, USA.

Stephanie Mazzucca (S)

Prevention Research Center in St. Louis, Brown School, Washington University in St. Louis, One Brookings Drive, Campus Box 1196, St. Louis, MO, 63130, USA.

Margaret Padek (M)

Prevention Research Center in St. Louis, Brown School, Washington University in St. Louis, One Brookings Drive, Campus Box 1196, St. Louis, MO, 63130, USA. mpadek@wustl.edu.

Ross C Brownson (RC)

Prevention Research Center in St. Louis, Brown School, Washington University in St. Louis, One Brookings Drive, Campus Box 1196, St. Louis, MO, 63130, USA.
Department of Surgery (Division of Public Health Sciences), Washington University School of Medicine, Washington University in St. Louis, St. Louis, MO, 63103, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH